Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family, Community, and Opportunity at The Heritage Foundation, discusses the policies under the Trump administration and how they will affect financial burdens.
Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family, Community, and Opportunity at The Heritage Foundation, discusses the policies under the Trump administration and how they will affect financial burdens.
Transcript
Do you think the Trump administration’s decision to extend the life short-term health plans will have an impact on the financial hardships many patients face?
The Trump administration’s move to restore the previous definition of short term plans would provide an out in the near term for people who are self-employed, for example, and get no subsidies for coverage because they would be able to have less expensive coverage. Over the longer run, I think those people will probably move towards association plans which is something else that the Trump administration put forward.
What policy change might help alleviate financial burdens facing patients as new, potentially curative but expensive, treatments come to market to ensure patients have access to these innovative medications?
The treatments are primarily pharmaceutical therapies, biologics in particular. I think we’re seeing already in the private sector integrating those benefits with hospital and physicians. Otherwise, not treating them as separate. We have situations where yes, the pharmaceutical therapy is expensive but it’s not different than a surgery, it’s just were more used to paying large dollars for a surgery opposed to paying large dollars for pharmacy. The use of separate deductibles and things like that is sort of going away in the private market. The government programs, particularly Medicare, haven’t kept up with that and that’s where it needs to be integrated.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More